The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive top-line results from the Phase 3 OPTIMUM study, which evaluated the efficacy and safety of ponesimod compared to Aubagio® (teriflunomide) in adults with ...
NeuroRx announced statistically significant final results from its Phase 2 STABIL-B study of NRX-101 versus lurasidone in patients with Severe Bipolar Depression and Acute Suicidal Ideation or Behavior (ASIB).
89bio LTD announced positive top-line results from a Phase 1 single ascending dose (SAD) study of its investigational medicine, BIO89-100, in healthy volunteers.